Want to see JP:4967 full AI Analyst Report?
4967 Stock Chart & Stats
¥5368.00
¥13.00(0.22%)
At close: 4:00 PM EST
¥5368.00
¥13.00(0.22%)
Day’s Range― - ―
52-Week Range¥5,030.00 - ¥6,140.00
Previous CloseN/A
Volume384.70K
Average Volume (3M)221.72K
Market Cap
¥413.01B
Enterprise Value¥373.79K
Total Cash (Recent Filing)¥65.03B
Total Debt (Recent Filing)¥727.00M
Price to Earnings (P/E)134.2
Beta0.28
Next Earnings
Aug 06, 2026EPS Estimate
24.21Next Dividend Ex-DateN/A
Dividend Yield1.95%
Share Statistics
EPS (TTM)41.28
Shares Outstanding78,050,000
10 Day Avg. Volume218,190
30 Day Avg. Volume221,720
Financial Highlights & Ratios
PEG Ratio-1.73
Price to Book (P/B)1.91
Price to Sales (P/S)2.43
P/FCF Ratio32.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)140.67
Revenue Forecast (FY)¥172.69B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMinimal debt and large stable equity provide durable financial resilience. Low leverage reduces solvency risk, preserves borrowing capacity for capex or M&A, and supports ongoing operations and payouts during cyclical weakness, strengthening strategic optionality over months.
Improved Cash Generation (2025)A material rebound in operating cash flow and return to positive free cash flow improves funding reliability. Sustained cash generation supports reinvestment in product development, marketing and distribution, lowers reliance on external financing, and underpins longer-term operational plans.
Stable Branded Consumer BusinessCore sales of everyday OTC and household brands sold through broad retail and online channels produce recurring demand. Brand recognition and repeat purchase behavior support predictable revenue streams and margin stability, aiding planning and resilience across multi-month horizons.
Bears Say
Sharp Profitability DeteriorationA steep multi-year decline in net income signals material margin pressure and weakening operating performance. Persistently lower profits constrain reinvestment, limit flexibility on pricing or promotions, and erode long-term returns unless structural cost or revenue drivers are restored.
Volatile Cash ConversionLarge swings in free cash flow indicate inconsistent conversion of earnings into liquidity. Such volatility complicates capital allocation, may force short-term funding measures or deferrals of investment, and raises execution risk for multi-month growth or restructuring plans.
Low Growth And Weakening ReturnsModerate top-line growth and a marked drop in ROE to ~4.7% reflect reduced capital efficiency. Over the medium term this limits the company's ability to generate attractive returns on incremental investment and may require strategic changes to restore growth and profitability.
Kobayashi Pharmaceutical Co News
4967 FAQ
What was Kobayashi Pharmaceutical Co Ltd’s price range in the past 12 months?
Kobayashi Pharmaceutical Co Ltd lowest stock price was ¥5030.00 and its highest was ¥6140.00 in the past 12 months.
What is Kobayashi Pharmaceutical Co Ltd’s market cap?
Kobayashi Pharmaceutical Co Ltd’s market cap is ¥413.01B.
When is Kobayashi Pharmaceutical Co Ltd’s upcoming earnings report date?
Kobayashi Pharmaceutical Co Ltd’s upcoming earnings report date is Aug 06, 2026 which is in 20 days.
How were Kobayashi Pharmaceutical Co Ltd’s earnings last quarter?
Kobayashi Pharmaceutical Co Ltd released its earnings results on May 08, 2026. The company reported ¥13.95 earnings per share for the quarter, beating the consensus estimate of ¥5.38 by ¥8.57.
Is Kobayashi Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Kobayashi Pharmaceutical Co Ltd’s price is currently Overvalued.
Does Kobayashi Pharmaceutical Co Ltd pay dividends?
Kobayashi Pharmaceutical Co Ltd pays a Semiannually dividend of ¥61 which represents an annual dividend yield of 1.95%. See more information on Kobayashi Pharmaceutical Co Ltd dividends here
What is Kobayashi Pharmaceutical Co Ltd’s EPS estimate?
Kobayashi Pharmaceutical Co Ltd’s EPS estimate is 24.21.
How many shares outstanding does Kobayashi Pharmaceutical Co Ltd have?
Kobayashi Pharmaceutical Co Ltd has 78,050,000 shares outstanding.
What happened to Kobayashi Pharmaceutical Co Ltd’s price movement after its last earnings report?
Kobayashi Pharmaceutical Co Ltd reported an EPS of ¥13.95 in its last earnings report, beating expectations of ¥5.38. Following the earnings report the stock price went up 1.443%.
Which hedge fund is a major shareholder of Kobayashi Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4967
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kobayashi Pharmaceutical Co Ltd
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, Southeast Asia, and internationally. The company offers Ammeltz, an anti-inflammatory pain relief medicine; Dent, an effervescent denture cleaning agent; Ekitai Bluelet Okudake, a toilet bowl cleaner; Naicitol, a Chinese herbal medicine that promotes the breakdown and metabolism of fat; BreathCare, an oral breath freshener capsule; Netsusama sheet, a cooling gel sheet; and deodorizing air fresheners, lens cleaners, and oral hygiene products. It also manufactures and sells pharmaceuticals, fragrances, deodorants, cosmetics, health food, synthetic resin processed products, paper products, and hand warmers; and sells daily necessities. In addition, the company engages in transportation, real estate management, advertising planning and production, sales promotion and market research, promotional goods production and sales, and asset management activities, as well as in pharmacy, retail, and cleaning industries. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.